Edesa Biotech Inc./$EDSA
1D1W1MYTD1Y5YMAX
Capital at risk
About Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
- Ticker
- $EDSA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Markham, Canada
- Website
- www.edesabiotech.com
EDSA Metrics
BasicAdvanced
$56M
-
-$1.73
1.08
-
Price and volume
Market cap
$56M
Beta
1.08
52-week high
$20.32
52-week low
$0.72
Average daily volume
75K
Financial strength
Current ratio
2.757
Quick ratio
2.701
Profitability
EBITDA (TTM)
-14.525
Effective tax rate (TTM)
-0.01%
Management effectiveness
Return on assets (TTM)
-66.43%
Return on equity (TTM)
-122.93%
Valuation
Price to book
99.96
Price to tangible book (TTM)
-26.54
Price to free cash flow (TTM)
-3.784
Free cash flow yield (TTM)
-26.42%
Free cash flow per share (TTM)
-1.094
Growth
Earnings per share change (TTM)
38.25%
3-year earnings per share growth (CAGR)
-21.21%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.